s ("VMS") category driven by increased competition and increased retail shipments of infant formula placed in the fourth quarter of fiscal 2012 in advance of the planned July 1
st shutdown of the Company's Vermont Plant to perform an SAP conversion and prepare for the installation of a new packaging line. Reported and adjusted gross profit and margin were impacted by relatively lower volumes in infant formula and VMS, along with increased inventory costs.
Operating income and margin were impacted by higher combined research and development and distribution, selling, general and administration expenses as a percent to net sales, though they were lower on a dollar basis, year-over-year.
Rx PharmaceuticalsRx Pharmaceuticals Segment
(in thousands)
(see the attached Table II for reconciliation to GAAP numbers)Fiscal 2013
Fiscal 2012First Quarter
Ended
First Quarter
Ended
YoY 9/29/2012
9/24/2011
% ChangeNet Sales
$162,942
$127,627
27.7%Reported Gross Profit
$86,684
$41,460
109.1%Adjusted Gross Profit
$95,086
$75,992
25.1%Reported Operating Income
$68,504
$24,485
179.8%Adjusted Operating Income
$76,906
$58,673
31.1%Reported Gross Margin
53.2%
32.5%
+2,070 bpsAdjusted Gross Margin
58.4%
59.5%
-110 bpsReported Operating Margin
42.0%
19.2%
+2,280 bpsAdjusted Operating Margin
47.2%
46.0%
+120 bpsThe Rx Pharmaceuticals segment first quarter net sales increased 28% to $163 million due primarily to incremental net sales of $19 million from the July 26, 2011 Paddock acquisition, new product sales of $8 million and improved pricing on select products.
Year-over-year percent changes in reported gross profit and operating inco
'/>"/>
SOURCE Perrigo Company Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Related medicine technology :1.
Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 20122.
Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance3.
Perrigo Company to Present at the Bank of America Merrill Lynch 2012 Healthcare Conference4.
Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules5.
Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream6.
Perrigo Announces FDA Final Approval Of Tris Pharmas Dextromethorphan Polistirex Extended-Release Oral Suspension7.
Perrigo Company To Present At The William Blair Growth Stock Conference8.
Perrigo Receives FDA Approval And Commences Launch Of Clobetasol Propionate Shampoo, 0.05%9.
Perrigo Company Announces Quarterly Dividend10.
Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference11.
Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million